Good all very XXXX evening, would you thank I you much. Thank call. to for like QX our joining everyone. shareholder
year. for XXXX, expect or will we can update During of terms development Company shareholder also things business be how call, up next what this I'll that to provide see future. few see call see our wrapping on in for to in with this on our we Since progress the year last a has near expect I'll made end and a this words we the
that on at recap quarterly report was end last begin of of with Form a Let week. filed me the our XX-Q
of of million growing quarter. million in this QX pathology As in recent we top core threefold almost $X.X great progress the in year servicing, from to last line, made business our you saw, $X.X
of already XXXX, per life, to than equates XXXX, cases under less to whereas up still nine same in QX in and patient day. to we X,XXX cases, the number the months in average we X slightly X,XXX eclipsed first from day, This an per period that of XX bring to complete. Just have tested months nine
has also during translates this time economies And starting Our while the than proportionately of customers additional increasing volume more as count see increasing customer staffing our repeat doubled this we're needs, with of case into operations. scale well.
our the great essentially growing produce For gross the nine for the costs efficiencies a impact first eye seeing margin. XXXX. on line in jump the to in from while and our improving to X% XXXX, start focus of It's keen that keeping gross nine XX% went months top on same margin in months our
improvements. continue As on continue external metrics yield will we move generate QX into operation to lab our XXXX, gross growth capital. to reducing profits, to business project through we and Overall, our dependence
to move let's our product Now, side.
We continue to progress two IV-Cell HemeScreen. and our flagship great products, make with
surprising us At a launched the labs are gives to thank IV-Cell, also this and since media product very a recognize have also IV-Cell, into the promising. own key our in own our and the ADS done we not us facilitating of our of only this our in who their used this and confidence building we've is to product. reputable they've experience This our several most with customer some moving try years user and own our important of phase U.S. as labs Biotec, lab of the and beta initial partner, credibility These but Number prominent IV-Cell bringing world. Number like now. from two, Europe, have isn't steering of the new outcomes these some two is I'd reference results away of product using an we'll now this point, Knowing inventor that customers site from lab from in for we've discussions in in This terrific to and product laboratories We points. customers. to new For to media been years the gain beta in the one testing existing and ours. are phase. IV-Cell credibility of benefit needed of the gaining for compared of factor adopt the our hope will achieve products. see job the labs
As our door highly opener small knows and some industry. be Everyone other from to the of laboratories other. up I've mentioned these a will is as customers. many customers this regarded thumbs reputable before, each And immediate getting an
As we make strong progress public, including on-boarding will testing the to continue new and share we labs, continue will IV-Cell. the we begin to the the of on-boarding On customers. using to that progress who completion of HemeScreen, make phase progress, more
have a strong quarter. next Just of this our for in this completed customers week, we pipeline and several training lab and new
we base it client online margin, our chain, HemeScreen our working business. product of the their impact and to more strategically -- data to management, building we this ordering does side broaden easy financially? From strategy our to our of this to and high builds, several to reach for this from the prove perspective, As HemeScreen oncologists community partnerships the manage revenue continue complete points our our to products. on the Company inventory orders nationwide. system, end add also support a of of manufacturing to mean we works. to begin that We're What to the for business will strategic customers model year, and a backbone will of supply complete making recurring by Operationally, see entire
and which superior to to We diagnostic provides services core their have services our customers our pathology patients. business,
customer can that to first to the into technologies. expertise As these we those clinically, products. move we're leveraged competing operate in a we've create labs our knowledge them commercialize technologies technologies current testing use extensively by we essentially and and products the to privy lab, to weaknesses lab, After proprietary of our used becoming then
we purchased Both labs. to services our from identification sides technologies, proprietary business and those to of the the the laboratory to other of of new by growth conversion So, are products, success. key technologies into moved then
services create providing margin technologies. pay really our patients also for pathology line service new what will create focused bottom team grow we are are diagnostic But the R&D is by will the products playground of to what top Our laboratory quality way a and the physicians uniquely, their on pathology bills, perspective, Company. a surfaces high the a provide From high qualified the but and the of is financial accuracy. immense where -- highly services to sorts value
projects. technology discuss test business. to I'm to with of like that It reemphasize first the COVID move opportunity both the I’d to a is not to as our FDA testing, we well however care file again to market. let's part for that it the of is bring Now, have today major harvest have COVID our we at pleased to necessary home. announce chronic completed as core studies and the
we before, share approval with or publicly those cannot stated the studies of results the the we As FDA. process of
meet is we and for our level requires our product the of the believe view and However, threshold approval. that FDA study scrutiny the results it
this This received the news, developed kit the EUA virus of following to for those not virus. product our has test with infected the is kits. provided promising of virus, for ours. tests a after whereas development So, of EUA the at-home very is who've the that for presence person presence however been exciting the This for us. the a and antibodies product the the week test been you FDA competing first The
forward. facilities, think, to I need the on extend notion untrained there's This take market question individuals week’s clear that comfortable test conducting with to people ready and enable clearly to the to the take take for The testing FDA big long consensus safety within of their announcement themselves. the the the laboratories the how would FDA medical important of it that to is indicates was get beyond the tests home. step
today, of test of antibody one at-home use has only not FDA yet and care has As any the approved for test use. antibody for approved point
rapid test. seen by Some may recent for announcement a at-home of have you Costco the
the to read days it If then collection which to which however, the out lab, sample turns a three this gets with later. sent two received you details, is kit, results
neither we an when takes send two in in-lab actually rapid. very care After in the three of essentially immediate get to easy doctor opinion, results, that testing the to to days the confused their it different that that into lab. of by to it's One tend And least it if welcome eat it that raised a notion. our get agree at was given I test the nor model. results, this get is From perspective, do all why our could definitions, with with a test, this So, particularly these is would it's and business. to was prefer and I pandemic. at-home question do all, and office appreciate products point surrounded will
First of it's patient all, better care.
Second, recognition an versus where FDA entire lab the of granting samples, strong and need the of point need to exciting customers. of margins the tests at-home COVID of to to for store reduces we the test have these in-lab first the then kits, the results sale tubes to favor report our forward. a as running EUA an strongly our of having opposed The financial an operation the is care and to available FDA's our distributing by test kits signal masses. to it customers, to selling The and shipped basically the collected, operations operation. run step back to an make blood It's to receive virus the
and the within public to right the believe needs. FDA predict our the to is review that reach and our results timeline produces of that required for product the by -- results, the strong to our impossible it's Although health fit we review complete are it
whether our the full we Some say six vaccine unnecessarily of least me of months from that let away render of tests the broad in to at asked population. vaccine the are first, deployment you our will presence opinion,
Secondly, -- doesn't opportunity. those test availability antibodies. a we And will will there's the How know and will will how if be we that How this vaccine questions huge immune long the vaccine for All we We an is effects believe a is will generate how if intended potential still develop the our in last. vaccines through to the hamper response have of the antibody body that vaccine will successful? the system the developed? antibodies test. know cause to answered
increased production for ongoing for that In given and A there's from vaccine antibody The shelters the to tests screening explored still interesting that demand, indeed be and has is a less next with fact, what be areas will of has the developed also presence need does that undoubtedly virus In the of that is hold rationale vaccine ensure summary, to vaccine. effective. the the what antibody our been various see. as person vaccine a we can one that expect of comment that used idea for eligibility. the person vaccine reviewing becomes available. to the limited they smart the infected a idea vaccine as us? this suggested the will has business, the believe recent and here's demand to we still huge antibody, the In This extent testing are generate already our very likely is the behind year
to margin flow the our to continue to and pathology see increase to expect growth in cash business we For steady rapid services, breakeven. get
with followed expect by the the business nice that growing, adoption revenue, be the media the completion of partner the a generate a beta line. we study For labs to to bottom significant The rollout several and contributions to by of IV-Cell, anticipate ADS recurring Biotec. business global high-margin media will see prominent our we
customer base four-year program a of for large platform. will reagent assays. and who office an laboratories commitment strong expected the generating an cash For growing HemeScreen, a business. of Reagent will oncology all we base adopt running Rental This HemeScreen and plan, margins The installed building sites, physician projected us the anticipate our flow give is
We our positive a Company outside With reach believe gradual and impact it's capital. for breakeven. sources the approach reduction expected substantial, we of our the see on within would these financial success reliance businesses, of to of
the team, the for the and strategy, products. products, demand We those have the market
our the a enough we're of have actually size weather so For -- society far. best XX growth Despite and we've our we've in strong challenges and economy got we've demonstrated many on. Company best this our our year, so our or history faced employees, to the the a of that storm, shown going results lot Company's
forward in As all and figure of safety, our to much I Have model season. themselves XXXX. out dramatic Thank business end families, their to health your with holiday many year you very and a look I nice a and sharing evening. ongoing we, for poised companies us strategy, think and you, and your successes. everyone thank happy reinvent steps and for and we for a support want this I you. so wish
